The Looming Antimicrobial Resistance (AMR) Pandemic: Opportunities for Investors

The COVID-19 pandemic has highlighted the vulnerabilities of societies and economies to infectious diseases and has given new importance to planning and preparedness for future pandemics. Policymakers, business leaders, and investors can stay aware of potential future health crises through analysis of emerging trends.

One such trend is antimicrobial resistance (AMR). AMR was already an emerging public health threat before COVID, and the U.S. Centers for Disease Control and Prevention (CDC) have identified the COVID-19 pandemic as an incubator for AMR. Even high-income countries are facing the burden of alarming AMR levels, despite the availability of more expensive second-line antibiotics. While healthcare companies can play a key role in tackling this crisis, they are also facing major vulnerabilities of their own.